PROLooking for more than just a company report? Upgrade to Pro now

HATAY PHARMACEUTICAL JOINT STOCK COMPANY

Active

Business ID 0500391400

84-24 / 3352 2525 / 3776 3172 / 2214 3368

HATAY PHARMACEUTICAL JOINT STOCK COMPANY

Active

Business ID 0500391400

84-24 / 3352 2525 / 3776 3172 / 2214 3368

HATAY PHARMACEUTICAL JOINT STOCK COMPANY

Active

Summary

Name:

HATAY PHARMACEUTICAL JOINT STOCK COMPANY

Business ID (TIN):

0500391400

Date of Registration:

10 Jan 2001

Registered Office:

Ha Noi City Department of Finance

Ticker:

DHT

Address:

No. 10A, Quang Trung Street, Ha Noi City, Vietnam

Phone:

84-24 / 3352 2525 / 3776 3172 / 2214 3368

Financial Statement:

2020, 2021, 2022, 2023, 2024

Ha Tay Pharmaceutical Joint Stock Company, known commercially as Hataphar, is one of Vietnam’s most established pharmaceutical manufacturers. Founded in 2001, the company specializes in the production and distribution of medicinal drugs, healthcare chemicals, and over-the-counter products. With more than two decades of operation, Hataphar has built a strong brand presence across Vietnam’s healthcare industry, recognized for its product quality, safety, and adherence to international pharmaceutical standards.

In 2023, Ha Tay Pharmaceutical reported total assets of USD 75.52 million and sales of USD 82.14 million, reflecting an 8.81 percent increase in revenue compared to 2022. Despite a 10.11 percent decline in profit, totaling USD 3.65 million, the company strengthened its capital structure, with equity rising 33.59 percent to USD 43.84 million. Supported by a workforce of 585 employees, Hataphar continues to expand its production capacity and market reach across Vietnam and neighboring regions.

Ha Tay Pharmaceutical Joint Stock Company is publicly listed on the Hanoi Stock Exchange (HNX) under the ticker symbol DHT.

Key personnel

The company is led by Chairman L.V. Lô, who oversees corporate strategy and governance. Supporting him are General Director L.X. Thắng, responsible for operations and production, and Deputy Chairman and Deputy General Director L.A. Trung, who manages business development and partnerships. Together, the leadership team has cultivated a management culture based on sustainability, innovation, and continuous improvement.

Ha Tay Pharmaceutical’s shareholder base includes both domestic and foreign investors. Aska Pharmaceutical Co., Ltd. of Japan serves as a strategic partner, bringing international expertise in pharmaceutical technology and manufacturing practices. Other key shareholders include L.V. Lô, L.V. Linh, H.V. Tuệ, and L. A Trung, representing the company’s combination of family-led management stability and external collaboration. This balanced ownership structure supports Hataphar’s continued modernization and global integration.

Financial Growth and Market Risks

Ha Tay Pharmaceutical has shown consistent financial expansion over recent years. In 2023, total assets increased by 25.09 percent, while owner’s equity grew by 33.59 percent, demonstrating strong internal financing and reinvestment capacity. Although net profit decreased due to rising input costs and competitive market conditions, the company maintained stable operations and profitability through efficient cost management and product diversification.

Operating in Vietnam’s dynamic pharmaceutical sector, Ha Tay faces challenges such as raw material price volatility, regulatory changes, and intensifying competition. However, its well-capitalized balance sheet, disciplined management, and established brand provide resilience against market pressures, ensuring sustainable long-term growth.

Business Information and RISKS

Based on current financial data and market conditions, Ha Tay Pharmaceutical Joint Stock Company is positioned for steady growth, supported by Vietnam’s expanding healthcare infrastructure and the rising demand for domestically produced medicines. The company’s strong asset base, robust equity growth, and modern manufacturing systems ensure continued competitiveness and operational stability.

What distinguishes Ha Tay Pharmaceutical is its vertically integrated business model, combining manufacturing, packaging, and distribution within a single corporate framework. The company operates advanced production facilities in Ha Noi and maintains additional branches in Ba Vi and Thuong Tin, allowing for nationwide coverage and efficient logistics. Its compliance with Good Manufacturing Practice (GMP) standards and collaboration with Aska Pharmaceutical Japan enhance its technical capacity and export readiness.

As Vietnam’s healthcare sector continues to expand, Ha Tay Pharmaceutical is well-positioned to capture new market opportunities, particularly in the prescription and OTC drug segments, while maintaining its reputation for quality and innovation.

VNBIS and Business Information Services

Vanguard Business Information LLC (VNBIS) provides a full suite of professional intelligence services designed to help investors and partners make informed business decisions when engaging with Ha Tay Pharmaceutical Joint Stock Company. These include:

Company Credit Reports assessing financial performance, solvency, and liquidity
Risk Management Solutions analyzes debt exposure, equity trends, and profitability risks
Business Verification and Due Diligence Reports, ensuring transparency in ownership, governance, and compliance

Through these services, VNBIS enables clients to evaluate Ha Tay Pharmaceutical’s financial stability, operational structure, and market potential with confidence, thereby ensuring secure, data-driven business relationships.

Legal Profile

English Name:

HATAY PHARMACEUTICAL JOINT STOCK COMPANY

Vietnamese Name:

CÔNG TY CỔ PHẦN DƯỢC PHẨM HÀ TÂY

Short Name:

HATAPHAR.

Business ID (TIN):

0500391400

Date of Registration:

10 Jan 2001

Registered Office:

Ha Noi City Department of Finance

Ticker:

DHT

Ownership Status:

Publicly held

Operation Status:

Active

Contacts

Key Decision Makers:

+ LE V.L

+ LE A.T

+ LE X.T

+ NGUYEN B.L

+ NGO T.V

+ LE V.L

+ HOANG V.T

Address:

No. 10A, Quang Trung Street, Ha Noi City, Vietnam

Phone:

84-24 / 3352 2525 / 3776 3172 / 2214 3368

Factory Address:

Group 4, La Khe Ward, Ha Dong District, Ha Noi City, Vietnam

Branch:

Van Trai Village, Ba Vi District, Ha Noi City, Vietnam

Branch:

No. 251, Ga Street, Ha Noi City, Vietnam

Branch:

No. 92, Group 3, Te Tieu Village, Ha Noi City, Vietnam

Branch:

No. 78, Quang Trung Street, Ha Noi City, Vietnam

Branch:

4th Floor, No. 10A, Quang Trung Street, Ha Noi City, Vietnam

Branch:

Lot 13, Group 22, Doc Den Street, Resettlement Area, Hung Yen Province, Vietnam

Branch:

No. 80, Nguyen Trai Street, Nghe An Province, Vietnam

Business Sector

Key business lines:

VSIC:

2100 Manufacture of pharmaceuticals, medicinal chemical and botanical products

NACE:

21.10 Manufacture of basic pharmaceutical products

Industry Sales Growth

CAGR (2019 - 2023)

-2.80%

YoY (2023)

-5.39%

Companies by industry

Company distribution and propportions

1,859

0.0639%

Key Industry Players

Top 10 companies in manufacture of pharmaceuticals, medicinal chemical and botanical products industry

dhg pharmaceutical joint-stock company vietnam pharmaceutical corporation traphaco joint stock company sanofi-aventis vietnam company limited imexpharm corporation hatay pharmaceutical joint stock company rohto-mentholatum (vietnam) co., ltd tenamyd pharmaceutical corporation sanofi vietnam shareholding company stellapharm j.v. co., ltd. – branch 1

Payment History

Purchase the report to access company details.

Financial Performance

Assets	64.11%
Owner’s Equity	-95.57%
Working Capital	-23.06%
Net Worth	-46.99%
Sales	-82.99%
Operating income	-35.79%
EBIT	-28.55%
Gross Profit Margin	-79.92%
Debt to EBITDA	75.58%

📈 📊

Company Reports

Company Profile Report

Legal Profile

Contact and Location

Legal Representative

Shareholders

Business Operation

Assets

Owner's Equity

Sales

Profit

Company Standard Report

Legal Profile

Business Locations

Legal Representative

EBT

EBITDA

Working Capital

Tangible Net Worth

Financial Ratios

Balance Sheet

Profit and Loss Statement

Cash Flow Statement

Comprehensive Report

Report Summary

Legal Profile

Historical Information

Business Locations

Subsidiary and Affiliated Company

Management and Directors

Shareholders

Business Operation

Suppliers

Buyers

Credit Limit

Industry Information

Key Industry Players

Competitors

Negative Payment Records

Banking Information

Litigation Records; Negative News

Financial Ratios

Balance Sheet

Profit and Loss Statement

Cash Flow Statement

Opinion from Analysts

Specific Questions About HATAY PHARMACEUTICAL JOINT STOCK COMPANY

When did HATAY PHARMACEUTICAL JSC start operating?

HATAY PHARMACEUTICAL JSC was started in 10 Jan 2001

What industry does HATAY PHARMACEUTICAL JSC operate in?

HATAY PHARMACEUTICAL JSC is operating in "Manufacture of pharmaceuticals, medicinal chemical and botanical products" industry

How can I contact HATAY PHARMACEUTICAL JSC?

HATAY PHARMACEUTICAL JSC phone numbers is 84-24 / 3352 2525 / 3776 3172 / 2214 3368

What adverse news is there about HATAY PHARMACEUTICAL JSC?

HATAY PHARMACEUTICAL JSC’s has 2 bad news

What is stock symbol of HATAY PHARMACEUTICAL JSC?

HATAY PHARMACEUTICAL JSC’s stock symbol is DHT

Where is the location of HATAY PHARMACEUTICAL JSC?

HATAY PHARMACEUTICAL JSC is located at No. 10A, Quang Trung Street, Ha Noi City, Vietnam

What is HATAY PHARMACEUTICAL JSC’s business registration?

HATAY PHARMACEUTICAL JSC business registration is 0500391400

My Order (0)

HATAY PHARMACEUTICAL JOINT STOCK COMPANY

HATAY PHARMACEUTICAL JOINT STOCK COMPANY

HATAY PHARMACEUTICAL JOINT STOCK COMPANY

Key personnel

Financial Growth and Market Risks

Business Information and RISKS

VNBIS and Business Information Services

Company Profile Report

Company Standard Report

Comprehensive Report

GET IN TOUCH FOR EXCLUSIVE DEALS!

We've just released an update!

Don’t miss any of our insights

HATAY PHARMACEUTICAL JOINT STOCK COMPANY

HATAY PHARMACEUTICAL JOINT STOCK COMPANY

HATAY PHARMACEUTICAL JOINT STOCK COMPANY

Key personnel

Financial Growth and Market Risks

Business Information and RISKS

VNBIS and Business Information Services

Company Profile Report

Company Standard Report

Comprehensive Report

GET IN TOUCH FOR EXCLUSIVE DEALS!

Access Required

Notification